Latest Posts:

Sorry, no posts matched your criteria.

Follow Us:

Back To Top

JOIN OUR EFFORTS TO

cure cystic fibrosis

BY LAUNCHING NEW THERAPEUTICS VENTURES IN PARTNERSHIP WITH

JOIN OUR EFFORTS TO

cure cystic fibrosis

BY LAUNCHING NEW THERAPEUTICS VENTURES IN PARTNERSHIP WITH
The Challenge

Cystic Fibrosis (CF) is one of the most common genetic diseases that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. CF can be life-threatening, and people with the condition tend to have a shorter-than-normal life span. The mutational profile across CF patients is complex and while life-extending therapies exist for the most common mutations, large patient populations remain uncatered for, and curative therapies are lacking.

At DSV, together with the Cystic Fibrosis Foundation (CFF), we are focused on developing life saving new therapies for larger numbers of people with CF – including those with rare and nonsense mutations – and pursuing daring, new opportunities to one day develop a lifelong cure that targets the disease from every angle. 

 

The Opportunity for you

Joining DSV is a fantastic opportunity to develop concepts for and launch your own therapeutics startup. Working with us and our current founders, you’ll have access to a completely new kind of environment for creating science companies, one that does not start with university IP, but with a systematic rework of an opportunity area from first principles.

Working with the CFF will allow you to tap into their disease- expertise and the wealth of knowledge already existing as part of their scientific community. 

Within less than 12 months you will have developed a few promising concepts, built a team of multidisciplinary co-founders and experienced advisors, incorporated a new company and spun-out of DSV to start the early tech development / proof-of-concept work with investment secured from DSV and CFF.

 

Our offer

We’ll provide a competitive monthly consultancy fee whilst you’re developing the concept(s) for your new venture and support you with building a founding team, and securing investors. DSV and CFF guarantee pre-seed investment, taking only 20% of equity (compared to >51% TTO standards), leaving the rest to be split between you and your co-founders.

 

Our impact

We’ve so far built and invested in 9 brand new companies in the pharma: curative therapeutics sector including in neurodegeneration, oncology and infectious diseases.

 

Who should apply

You bring broad technical knowledge in gene therapy, cell therapy, cellular engineering or synthetic biology and have acquired deep hands-on understanding of how to develop new concepts or processes, design experiments etc.

Interest in science commercialisation is a must, coupled with a strong desire to build a company to make a huge positive impact within the pharma sector.

Ideally, you will have thought about key opportunities and challenges within the CF space before and have some knowledge of pulmonary diseases and molecular genetics.

You cannot wait to get started!

The Challenge

Cystic Fibrosis (CF) is one of the most common genetic diseases that affects the lungs and digestive system. The body produces thick and sticky mucus that can clog the lungs and obstruct the pancreas. CF can be life-threatening, and people with the condition tend to have a shorter-than-normal life span. The mutational profile across CF patients is complex and while life-extending therapies exist for the most common mutations, large patient populations remain uncatered for, and curative therapies are lacking.

At DSV, together with the Cystic Fibrosis Foundation (CFF), we are focused on developing life saving new therapies for larger numbers of people with CF – including those with rare and nonsense mutations – and pursuing daring, new opportunities to one day develop a lifelong cure that targets the disease from every angle. 

 

The Opportunity for you

Joining DSV is a fantastic opportunity to develop concepts for and launch your own therapeutics startup. Working with us and our current founders, you’ll have access to a completely new kind of environment for creating science companies, one that does not start with university IP, but with a systematic rework of an opportunity area from first principles.

Working with the CFF will allow you to tap into their disease- expertise and the wealth of knowledge already existing as part of their scientific community. 

Within less than 12 months you will have developed a few promising concepts, built a team of multidisciplinary co-founders and experienced advisors, incorporated a new company and spun-out of DSV to start the early tech development / proof-of-concept work with investment secured from DSV and CFF.

 

Our offer

We’ll provide a competitive monthly consultancy fee whilst you’re developing the concept(s) for your new venture and support you with building a founding team, and securing investors. DSV and CFF guarantee pre-seed investment, taking only 20% of equity (compared to >51% TTO standards), leaving the rest to be split between you and your co-founders.

 

Our impact

We’ve so far built and invested in 9 brand new companies in the pharma: curative therapeutics sector including in neurodegeneration, oncology and infectious diseases.

 

Who should apply

You bring broad technical knowledge in gene therapy, cell therapy, cellular engineering or synthetic biology and have acquired deep hands-on understanding of how to develop new concepts or processes, design experiments etc.

Interest in science commercialisation is a must, coupled with a strong desire to build a company to make a huge positive impact within the pharma sector.

Ideally, you will have thought about key opportunities and challenges within the CF space before and have some knowledge of pulmonary diseases and molecular genetics.

You cannot wait to get started!

Interviews ongoing for a full-time start in November

Interviews ongoing for a full-time start in November